The patent cliff is one of those phrases that sounds so decisivelike a switch flips, revenues tumble, and generic competition storms the gates.
But reality is rarely that clean.
A new post from DrugPatentWatch argues that the patent cliff is more myth …

The real patent is the weak one nobody challenged.
In pharma, weve all watched the movie: a blockbuster launches, competitors squint at the patent thicket, lawyers quietly dust off claim charts, and thensomewhere between warning letters and appeal br…

Pharma executives keep using a familiar phraseloss of exclusivityto describe what happens when a brand faces generic or biosimilar entry. It sounds clinical. It sounds objective. It sounds inevitable.
But heres the uncomfortable truth: for most drugs, …

The Prior Art Edge: Why Search Quality Beats Legal Firepower in Drug Patent Litigation
Patent litigation in pharma can look like an arms racebig law firms, aggressive pleadings, and endless motion practice. But in the trenches, the decisive advantage o…

Most drug patent fights are decided before the courtroom ever opens.
In theory, the legal system rewards right. In practice, drug patent litigation is often won by the side that did the better work product first: better prior art searching, better clai…

The Authorized Generic Strategy: How Brands Can (Quietly) Beat the Patent Cliff
The patent cliff is supposed to be a countdown to price erosion.
But in pharma, timelines are often suggestionsand competition doesnt always arrive the way investors expect…

Most investors assume the patent cliff story is simple: if a drug is protected, returns follow; if protection ends, revenues fall. Reality is messierand the gap between a truly defensible drug patent and a listed patent can be wider than most portfolio…

Patent strategy rarely fails loudly. More often, it fails quietlyone missed filing, one deadline slipped by a day, one almost that becomes too late. In a landscape where drug exclusivity is worth billions, even the smallest procedural misstep can cost …